Ability to target any disease-associated PPI
So far, only limited number of PPIs have been targeted, and PPIs dependent on post-translational modifications (PTMs) are particularly challenging. However, PROMEDIGEN's technology enables targeting any disease-associated PPI.
Proteins are expressed and purified from bacterial culture, and PTMs are site-specifically introduced. The purified proteins are then used for high throughput screening.
PROMEDIGEN is pursuing multiple, high-value PPI targets, building a strong pipeline